U.S. Will Update DNA Screening Standards on October 13
The new federal policy mandates screening based on biological function rather than sequence resemblance.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Will the government provide clear guidance for DNA screening standards before the October 13 deadline?
Beginning October 13, 2026, the National Science and Technology Council will implement updated screening standards for mail-order DNA synthesis. This shift moves the industry from checking sequence resemblance toward evaluating the specific biological function of sequences.
Why it matters
The updated standard is designed to improve the detection of dangerous molecules during the synthesis process. This change is intended to bolster national biosecurity by focusing on what a sequence does rather than how closely it matches known data.
The new framework requires DNA synthesis providers to screen customer orders for functional properties. These companies serve as the final checkpoint, converting text-based DNA sequence files into physical synthetic DNA vials.
The players
National Science and Technology Council
A cabinet-level council that coordinates science and technology policies across the federal government.
The details
DNA synthesis companies currently act as the primary filter for synthetic biological threats by identifying suspect sequences before they are printed. The updated protocol mandates that these firms shift their diagnostic focus from simple sequence matching—comparing requested DNA to databases of known pathogens—to evaluating the predicted biological function of the molecule. This transition forces firms to account for sequences that may not have a close match in existing databases but could still exhibit hazardous properties.
Timeline
October 13, 2026: The new screening standard officially takes effect.
The Tech Race
This policy change represents a shift in the U.S. approach to securing the synthetic biology supply chain. It moves beyond standard sequence-matching research and toward functional evaluation as the new baseline for preventing the creation of dangerous biological agents.
The change directly affects the workflow of commercial DNA synthesis firms operating within the United States. While the policy mandates a new screening standard, the lack of released government guidance means companies currently face uncertainty regarding the specific compliance protocols required by October 13.
The takeaway
The move to functional screening signals a shift in how the industry identifies synthetic biological risks. Readers should track the release of the federal government's missing implementation guidance to understand the specific compliance requirements that will govern commercial DNA orders.
Further reading
For more on the evolving standards for synthetic biology, visit Biotech.
Source note: This article includes information reported by Law360.
Live Poll
Will the government provide clear guidance for DNA screening standards before the October 13 deadline?
